OXURION

YOUR VISION IS OUR VISION™

PRESS RELEASE

Regulated Information

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

Leuven, BELGIUM – November 6, 2026 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation[1] it has received transparency notifications as follows:

Oxurion received a transparency notification on November 4, 2026, from Atlas Special Opportunities II indicating that as of November 3, 2026, it held 28,661,021 shares of the then outstanding 232,004,731 shares, and therefore crossed below the threshold (15%) by virtue of the sale of voting securities.

Oxurion received a transparency notification on November 5, 2026, from Atlas Special Opportunities II indicating that as of November 6, 2026, it held 19,086,684 shares of the then outstanding 232,004,731 shares, and therefore crossed blow the threshold (10%) by virtue of the sale of voting securities.

About Oxurion

Oxurion NV (Euronext Brussels: OXUR) is building a technology-enabled clinical research and software platform. The Company combines clinical operations expertise, software innovation and proprietary operational data to support pharmaceutical, biotechnology and medical device sponsors. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV
Pascal Ghoson,
Chief Executive Officer
Pascal.ghoson@oxurion.com

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

FSMA — FINANCIAL SERVICES AND MARKETS AUTHORITY

Transparency notification
Form TR-1 BE
PART I

1) Status of the notification

Final

2) Issuer

Name	OXURION
Identification number	0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights

4) Notification by

A person that notifies alone

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities II LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

Please continue entering the information in *part II* concerning the persons referred to in Sections 5 and 6

Part II

7) Date on which the threshold is crossed

03/11/2026 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

15

If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

232,004,731

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities II LLC	41,497,561	28,661,021		12.35%	
TOTAL		28,661,021	0	12.35%	0.00%

Start with "groups" of holders. Add subtotals with Σ, and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will be updated once you have clicked on *<CALCULATE>*.

B) Equivalent financial instruments	After the transaction					
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL				0	0.00%	

The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)		# of voting rights	% of voting rights
	CALCULATE	28,661,021	12.35%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities II LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder | will cease to hold / will hold again: 0 | voting rights as of (DD/MM/YYYY)

13) Additional information

On 20 October 2026 (with settlement date on 22 October 2026), Atlas Special Opportunities II LLC sold 11,764,303 shares in Oxurion NV, as a result of which its shareholding decreased to 41,497,561 shares (= 17.887%, denominator = 232,004,731)

On 21 October 2026 (with settlement date on 23 October 2026), Atlas Special Opportunities II LLC sold 319,476 shares in Oxurion NV, as a result of which its shareholding decreased to 41,178,085 shares (= 17.749%, denominator = 232,004,731)

On 23 October 2026 (with settlement date on 27 October 2026), Atlas Special Opportunities II LLC sold 408,977 shares in Oxurion NV, as a result of which its shareholding decreased to 40,769,108 shares (= 17.573%, denominator = 232,004,731)

On 30 October 2026 (with settlement date on 3 November 2026), Atlas Special Opportunities II LLC sold 12,108,087 shares in Oxurion NV, as a result of which its shareholding decreased to 28,661,021 shares (= 12.354%, denominator = 232,004,731)

Done at: New York

On: 03/11/2026 (DD/MM/YYYY)

Name & capacity: Patrick Vance, Proxyholder

Signature: Signed by: 9A8C4789B05442E...

Annex 2

FSMA — FINANCIAL SERVICES AND MARKETS AUTHORITY

Transparency notification
Form TR-1 BE
PART I

1) Status of the notification

Final

2) Issuer

Name: OXURION
Identification number: 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights

4) Notification by

A person that notifies alone

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities II LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

Please continue entering the information in ***part II*** concerning the persons referred to in Sections 5 and 6

Part II

7) Date on which the threshold is crossed

06/11/2026 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

10

If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

232,004,731

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities II LLC	28,661,021	19,086,684		8.23%	
TOTAL		19,086,684	0	8.23%	0.00%

Start with "groups" of holders. Add subtotals with Σ, and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will be updated once you have clicked on ***<CALCULATE>***.

B) Equivalent financial instruments	After the transaction					
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
	TOTAL			0	0.00%	

The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)		# of voting rights	% of voting rights
	CALCULATE	19,086,684	8.23%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities II LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder		will cease to hold / will hold again	0	voting rights as of (DD/MM/YYYY)	

13) Additional information

On 20 October 2026 (with settlement date on 22 October 2026), Atlas Special Opportunities II LLC sold 11,764,303 shares in Oxurion NV, as a result of which its shareholding decreased to 41,497,561 shares (= 17.887%, denominator = 232,004,731)

On 2 November 2026 (with settlement date on 4 November 2026), Atlas Special Opportunities II LLC sold 941,000 shares in Oxurion NV, as a result of which its shareholding decreased to 27,720,021 shares (= 11.948%, denominator = 232,004,731)

On 3 November 2026 (with settlement date on 5 November 2026), Atlas Special Opportunities II LLC sold 9,000 shares in Oxurion NV, as a result of which its shareholding decreased to 27,711,021 shares (= 11.944%, denominator = 232,004,731)

On 4 November 2026 (with settlement date on 6 November 2026), Atlas Special Opportunities II LLC sold 8,624,337 shares in Oxurion NV, as a result of which its shareholding decreased to 19,086,684 shares (= 8.227%, denominator = 232,004,731)

Done at: New York

On: 06/11/2026 (DD/MM/YYYY)

Name & capacity: Patrick Vance, Proxyholder

Signature: Signed by: 9A8C4789B05442E...